StageMerger | Merged
Hepregen, a spinout of MIT, is developing a platform to reduce the liver toxicity caused by approved drugs. The platform is based on technology developed by Sangeeta Bhatia, an associate professor in the Harvard-MIT Division of Health Sciences and Technology (HST) and MIT's Department of Electrical Engineering and Computer Science. The technology is based on engineered "miniature micro liver cells."
Missing: Hepregen's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Hepregen's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Hepregen
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Hepregen is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Hepregen has filed 4 patents.
Clusters of differentiation, Transcription factors, Cell biology, Human cells, Immunology
Clusters of differentiation, Transcription factors, Cell biology, Human cells, Immunology
Latest Hepregen News
Jan 17, 2023
| Organovo, Hepregen, Hurel Corporation, Nortis and AxoSim News Provided By Share This Article Organ-on-a-chip Market Analysis Organ-on-a-chip is gaining prominence on the backdrop of regulatory measures on animal testing and growing complexity in therapeutic applications. BURLINGAME, CALIFORNIA, UNITED STATES, January 17, 2023 / EINPresswire.com / -- “Coherent Market Insights offers Up to 45% discount on Healthcare IT Market Reports on Single User Access and Unlimited User Access“ Report Description: Coherent Market Insights presents an encyclopedic research of the Organ-on-a-chip Market with holistic insights into significant variables and features driving the future growth of the market. The Organ-on-a-chip Market was studied for the projected year 2023-2030 as well as the historical period 2017-2022. The research study provides complete qualitative and quantitative analysis to help shareholders obtain a thorough grasp of the Organ-on-a-chip Market and its crucial dynamics. The report provides a professional in-depth examination of the Organ-on-a-chip Market’s current scenario. CAGR, gross margin, revenue, price, production growth rate, volume, value, market share, and year-over-year growth are among the market data assessed and re-validation in the research. This detailed Organ-on-a-chip Market analysis is built utilizing the most latest primary and secondary research methodologies. We examined important markets such as North America, Europe, India, China, Japan, and MEA as part of the regional analysis. Leading company profiles are based on a range of factors such as markets served, production, revenue, market share, recent innovations, and gross profit margins. A specialized market dynamics section that gives an in-depth examination of the market’s drivers, constraints, opportunities, influencers, challenges, and trends. Request for Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/49 ** Note – This report sample includes: ▪️ Scope For 2023 ▪️ Table of Contents (Scope covered as a part of the study) ▪️ Top players in the market ▪️ Research framework (structure of the report) ▪️ Research methodology adopted by Coherent Market Insights The Prominent/Emerging Players in the Organ-on-a-chip Market includes: ✤ Organovo Organ-on-a-chip Market Dynamics: ▪️ Organ-on-a-chip is expected to cater to wide range of applications ranging from disease modelling to patient stratification and phenotypic screening. Most of the demand is expected to be generated from lung-based organ culture, followed by kidney application. The technology offers better clinical examinations compared to petri dishes and animal testing – helping scientists and companies to better understand the functioning of internal organs such as the brain and lungs. ▪️ Funding and government initiatives are projected to further boost market growth in the near future. Though the market is expected to create substantial opportunities, high cost and early stage in R&D are some of the factors leading to slow growth of the market. Market is expected to witness rampant commercialization post-2020. Regional Outlook: ➸ Europe (Germany, UK, France, Italy, Russia and Turkey, Rest of Europe) ➸ Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam Rest of Asia) ➸ South America (Brazil, Argentina, Columbia, Reset of South America) ➸ Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and Rest of South Africa & Middle East) The Key Findings of the Report: ▪️ This report describes the various situations of the entire market and provides a roadmap for how Organ-on-a-chip industry participants can gain a foothold in this rapidly changing market. Industry participants can reform their strategies and methods by checking the market size forecast mentioned in this report. The profitable segments/subsegments for the Organ-on-a-chip market have been revealed, which may affect the global expansion strategy of leading organizations. However, this research report has detailed information about each manufacturer. ▪️ The chapter on the analysis of key factors in the market focuses on technological progress/risks, substitution threats, changes in consumer demand/customer preferences, technological progress in related industries, and changes in the economic/political environment that attract market growth factors. ▪️ The research points to the fastest and slowest growing market segments to provide important insights into each core element of the market. New market participants started trading and accelerated the transition in the Organ-on-a-chip market. M&A activity is predicted to change the market structure of the industry. Leave a Query @ https://www.coherentmarketinsights.com/insight/request-customization/49 ▪️ Business description: a detailed description of company operations and business departments. ▪️ Company strategy: The analyst’s summary of the company’s business strategy. ▪️ SWOT analysis: Detailed analysis of the company’s strengths, weaknesses, opportunities, and threats. ▪️ Company History: The progress of major events related to the company. ▪️ Main products and services: A list of the company’s main products, services, and brands. ▪️ Main competitors: A list of the company’s main competitors. ▪️ Important locations and subsidiaries: The company’s main locations and subsidiaries’ list and contact information. ▪️ Detailed financial ratios of the past five years: The latest financial ratios come from the annual financial statements issued by companies with a history of five years. Table of Contents with Major Points: 1. Executive Summary 5.1. Market Snapshot 5.3. Global Organ-on-a-chip Market Estimates & Forecasts by Type 2018-2030 (USD Billion) 5.4. Organ-on-a-chip Market, Sub Segment Analysis 6. Global Organ-on-a-chip Market, by Application 6.1. Market Snapshot 6.3. Global Organ-on-a-chip Market Estimates & Forecasts by Application 2018-2030 (USD Billion) 6.4. Organ-on-a-chip Market, Sub Segment Analysis 6.4.1. Others 7.1. Market Snapshot 7.3. Global Organ-on-a-chip Market Estimates & Forecasts by Verticles 2018-2030 (USD Billion) 7.4. Organ-on-a-chip Market, Sub Segment Analysis 8. Global Organ-on-a-chip Market, Regional Analysis 8.1. Organ-on-a-chip Market, Regional Market Snapshot 8.2. North America Organ-on-a-chip Market 8.3. Europe Organ-on-a-chip Market Snapshot 8.4. Asia-Pacific Organ-on-a-chip Market Snapshot 8.5. Latin America Organ-on-a-chip Market Snapshot 8.6. Rest of The World Organ-on-a-chip Market 9. Competitive Intelligence
Hepregen Frequently Asked Questions (FAQ)
When was Hepregen founded?
Hepregen was founded in 2007.
Where is Hepregen's headquarters?
Hepregen's headquarters is located at 200 Boston Ave, Medford.
What is Hepregen's latest funding round?
Hepregen's latest funding round is Merger.
How much did Hepregen raise?
Hepregen raised a total of $6.81M.
Who are the investors of Hepregen?
Investors of Hepregen include Ascendance Biotechnology, National Science Foundation, Massachusetts Life Sciences Center, U.S. Department of Health and Human Services, Battelle Ventures and 4 more.
Who are Hepregen's competitors?
Competitors of Hepregen include Carmot Therapeutics, DiscoveryBioMed, Echelon Biosciences, Guava Technologies, BioNano Genomics and 12 more.
Compare Hepregen to Competitors
AureoGen is a research-based biotech company with a focus on discovery and production of commercially and clinically important cyclic peptide-based drugs, through genetic engineering of cyclic peptide producing organisms (as an alternative to complex and expensive synthetic chemistry methods). AureoGen's business is centered on generating intellectual property, both through discovery of genes, molecules and organisms and through development of technology and engineered organisms.
AC PharmaChem, Inc. is a fast growing company providing contract research and development services of medicinal chemistry, customer based organic synthesis of special chemical reagents, intermediates, reference compounds, and synthesis of focused libraries. The company's goal is to fully support the company's pharmaceutical and biotech partners to speed up and advance their drug discovery and innovation processes. At AC PharmaChem, the company have experienced medicinal and synthetic chemists utilizing synthetic techniques and instruments to provide cost efficient and on time delivery to meet the demands of the company's customers.
Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.
Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.
Glycopep is engaged in the synthesis and development of unique chemicals and resin products to support drug discovery. Glycopep is providing custom synthesis to academic institutions and pharmaceutical/biotech companies.
Trana Discovery, a drug discovery technology company, aims to help its partners find classes of drugs for the treatment of serious viral, fungal, and bacterial infectious diseases. The technology identifies compounds that work through a mechanism of action: inhibition of the target pathogen's ability to use transfer RNA (tRNA) essential for protein synthesis or replication. The use of Trana Discovery technology can unlock the value " scientific, human, and financial " hidden in drug compound libraries, expedite the discovery of drugs, and provide opportunities for exclusive rights to drug classes.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.